23andMe Faces Uncertain Future Amid Mass Layoffs and Leadership Exodus

23andMe is undergoing a major restructuring, laying off 40% of its workforce and cutting cancer research programs to focus on its core genetic testing business. This move follows the mass resignation of its board and a significant drop in market valuation. CEO Anne Wojcicki aims to stabilize the company by saving $35 million annually through these changes, despite challenges like a data breach and declining demand for DNA-testing kits.